Gilead Sciences and Novo Nordisk announce intent to initiate a clinical collaboration in NASH

This article was originally published here

The intended clinical trial will be a proof-of-concept study combining Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of

The post Gilead Sciences and Novo Nordisk announce intent to initiate a clinical collaboration in NASH appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply